Pharmaceutical Technology on MSN6d
GSK to acquire Chimagen’s CMG1A46 for autoimmune diseaseGlaxoSmithKline (GSK) has agreed to acquire Chimagen Biosciences’ CMG1A46, a clinical-stage therapy designed to target B cell ...
GSK (GSK) plc and Chimagen Biosciences, a privately held biotechnology company, announced an agreement for GSK to acquire ...
In a strategic move to enhance their immunology portfolio, GSK has announced an agreement to acquire experimental therapy ...
GSK inks agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline: London, UK Thursday, October 31, 2024, 10:00 Hrs [IST] GSK plc and Chimagen Bioscien ...
Discover the major biotech partnerships, collaborations, and mergers and acquisitions that made headlines in October 2024.
GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...
A Fierce 15 winner last year, Ventus said its drug, VENT-03, “was safe and well-tolerated at doses far exceeding those planned for use in Phase 2 trials.” The drug’s "favorable PK profile” supports ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback